NIH Highlighted Topic: Advancing Autoimmune Disease Research: Integrating Genetic, Environmental, and Immunological Factors to Improve Diagnosis and Treatment
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing autoimmune disease research through the integration of genetic, environmental, immunological, computational, and clinical approaches. This highlighted topic supports multidisciplinary projects designed to improve understanding of autoimmune disease development, progression, diagnosis, monitoring, and treatment across a wide range of conditions affecting millions of individuals in the United States.
NIH is particularly interested in projects investigating the interplay between genetics, the immunome, and the exposome—the cumulative environmental exposures experienced throughout life—to better understand autoimmune disease risk, prodromal stages, disease flares, and co-occurring autoimmune conditions. Companies developing AI-enabled diagnostics, predictive analytics platforms, digital health technologies, wearable sensors, bioinformatics tools, imaging systems, computational biology platforms, or novel biomarkers may be strong candidates for funding.
Areas of interest include point-of-care diagnostics, multimodal data integration, machine learning and AI for autoimmune disease prediction, longitudinal cohort analysis, wearable monitoring systems, imaging technologies, computational immunology, exposomics, precision medicine, and New Approach Methodologies (NAMs) for disease modeling. NIH is also encouraging projects addressing women’s health, aging, cancer immunology, neurological autoimmune disorders, health disparities, pediatric autoimmune conditions, and organ-specific autoimmune diseases.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on funding and commercialization support depending on project scope and translational impact.
This highlighted topic is supported by numerous NIH Institutes and Centers including ORWH, NIAID, NIBIB, NHGRI, NINDS, NCI, NIDDK, NIEHS, NIMH, NLM, and others, all of which are seeking transformative innovations that improve autoimmune disease diagnosis, prediction, monitoring, treatment, and patient outcomes.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of diagnostics, computational platforms, digital health technologies, biomarkers, imaging systems, and therapeutic tools related to autoimmune diseases.
Eligible activities may include:
AI and machine learning platforms for autoimmune disease prediction and diagnosis
Biomarker discovery and precision diagnostics for autoimmune conditions
Wearable sensors and remote monitoring technologies
Point-of-care testing and mobile diagnostic platforms
Computational biology and exposome analysis tools
Multi-omics data integration and bioinformatics systems
Imaging technologies for autoimmune disease monitoring
Predictive analytics platforms for disease progression and flare detection
Digital twins and computational disease modeling systems
New Approach Methodologies (NAMs) for autoimmune disease research
Clinical decision support tools and longitudinal patient monitoring platforms
Technologies supporting women’s autoimmune health and sex-specific disease research
Cancer immunology and autoimmune interaction research platforms
Neuroimmune and neurological autoimmune disorder research technologies
Pediatric and reproductive autoimmune health solutions
AI-driven health disparities and population health analytics
Data interoperability frameworks and collaborative research platforms
Prototype development, translational research, and validation studies
Commercialization planning, regulatory preparation, and scale-up activities
Funding may also support personnel, software development, cloud infrastructure, laboratory testing, clinical data analysis, bioinformatics pipelines, imaging analytics, AI model development, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare or biotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
